(Total Views: 277)
Posted On: 09/14/2018 1:32:09 PM
Post# of 86157
The DEA actually says they have no choice but to reclassify, only that one quote I highlighted below is of importance for us UNVC shareholders:
https://www.businessinsider.com/cost-first-fd...K&IR=T
Currently, CBD is scheduled alongside marijuana as a schedule 1 drug with "no currently accepted medical use." Beginning on June 25 when Epidiolex was approved, the agency had 90 days to reschedule or reclassify it as a schedule 2, 3, 4, or 5 substance.
"We don't have a choice on that," DEA public affairs officer Barbara Carreno told Business Insider in June. "It absolutely has to become Schedule 2, 3, 4, or 5."
https://www.businessinsider.com/cost-first-fd...K&IR=T
Currently, CBD is scheduled alongside marijuana as a schedule 1 drug with "no currently accepted medical use." Beginning on June 25 when Epidiolex was approved, the agency had 90 days to reschedule or reclassify it as a schedule 2, 3, 4, or 5 substance.
"We don't have a choice on that," DEA public affairs officer Barbara Carreno told Business Insider in June. "It absolutely has to become Schedule 2, 3, 4, or 5."
(2)
(0)Scroll down for more posts ▼
